Cigna Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +35

Cigna Group stock trades near consensus targets as analysts stick with Moderate Buy

AI-generated analysis

πŸ“ˆ Cigna Group stock closed at USD 275 with an average analyst price target of USD 337.10, implying approximately 22% upside potential.

πŸ“Š The company trades at a forward P/E ratio of 8.47, which is roughly 44% below the industry average of 15.27.

πŸ€– Cigna Group is deploying artificial intelligence across its health services platform to help rein in rising healthcare costs.

πŸ“‰ Recent performance shows Cigna shares rose 4.3% over six months, lagging the peer group's 36.4% industry growth rate.

πŸ’° Consensus estimates project 2026 earnings per share of USD 30.51, representing 2.3% year-on-year growth.

🏒 The company maintains a market capitalization of approximately USD 72.77 billion as of mid-September 2026.

πŸ“‰ Analyst consensus is Moderate Buy with 15 Buy and 8 Hold recommendations, and no Sell ratings recorded.

🎯 The current trading price sits near the middle of the 52-week range between USD 239.51 and USD 315.47.

βš–οΈ Zacks Investment Research assigns a Rank 3 (Hold) rating, balancing AI initiatives against competitive and regulatory risks.

πŸ“ˆ Reaching the average analyst target would place the stock modestly above its one-year high of USD 315.47.

Bullish Signals
  • Cigna Group trades at a forward P/E ratio of 8.47, significantly discounting the industry average of 15.27, suggesting undervaluation.
  • Analysts maintain a Moderate Buy consensus with an average price target of USD 337.10, implying roughly 22% upside from current levels.
  • The company is implementing artificial intelligence across its health services platform to manage rising healthcare costs effectively.
  • Consensus estimates project 2026 earnings per share growth of 2.3% to USD 30.51, indicating modest but positive earnings expansion.
  • Solid underlying earnings power and cash-flow profiles are cited as key reasons analysts expect positive total returns over the coming year.
Risk Factors
  • Cigna Group shares have risen only 4.3% over the past six months, significantly lagging the industry growth rate of 36.4%.
  • Zacks Investment Research assigns a Hold rating due to competitive and regulatory risks in the wider managed-care landscape.
  • The stock is priced below recent highs with around USD 40 of headroom to the 52-week high, indicating market caution on growth.
Full Analysis
Cigna Group stock closed at approximately USD 275 on September 18, 2026, trading near the mid-USD 270s as of September 19. The company carries a consensus rating of Moderate Buy among 23 analysts, with an average price target of USD 337.10 implying roughly 22% upside from current levels. Additional data from Simply Wall St suggests an average one-year target near USD 340.50 across 24 analysts, reinforcing the view that shares are undervalued relative to fundamental assessments. Valuation metrics highlight Cigna Group trading at a forward price-to-earnings ratio of 8.47, significantly below the industry average of 15.27, representing a discount of about 44%. Consensus estimates for 2026 earnings peg per-share growth at 2.3% to USD 30.51. The stock's market capitalization is approximately USD 72.77 billion, with the current price situated near the middle of its 52-week trading range between USD 239.51 and USD 315.47. Strategically, Cigna Group is leveraging artificial intelligence across its health services platform to manage rising healthcare costs, though recent performance has lagged peers with a six-month gain of 4.3% versus an industry increase of 36.4%. While analysts emphasize solid underlying earnings power and cash-flow profiles supporting potential total returns, the stock faces competitive and regulatory risks inherent in the managed-care landscape. The path to re-rating depends on execution in AI-enabled care management and cost control. Investors note that the combination of a discounted earnings multiple, double-digit implied upside relative to consensus targets, and Cigna's dividend and buyback policies may appeal to value-oriented strategies. However, divergent analyst ratings, including a Hold from Zacks Investment Research alongside Moderate Buy consensus, indicate mixed opinions on growth prospects versus policy risks. The near-term debate centers on whether the market is pricing in sufficient caution regarding growth and regulatory developments.